Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
TGRX-678 by Shenzhen Targetrx for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval
TGRX-678 is under clinical development by Shenzhen Targetrx and currently in Phase I for Chronic Myelocytic Leukemia (CML, Chronic Myeloid...